Delivers Outperformance Across All Fiscal Q3’23 Guided Metrics
Completes Audit Committee Investigation and Files Form 10-Q for Fiscal Q2’23
. | June 11, 2023
Recorded first quarter product revenue of $410.3 million, increasing 56.9% over $261.6 million from the prior-year period Launched BRUKINSA in the U.S. for adult patients with chronic lymphocytic
Recorded first quarter product revenue of $410.3 million, increasing 56.9% over $261.6 million from the prior-year period
Launched BRUKINSA® in the U.S. for adult patients with chronic. | May 4, 2023
Recorded product revenue of $349.5 million for the third quarter, representing an 82% increase from $192.5 million in the prior-year period BRUKINSA product revenue totaled $155.5 million, increasing
/PRNewswire/ - Indiva Limited (the "Company" or "Indiva") (TSXV: NDVA) (OTCQX: NDVAF), the leading Canadian producer of cannabis edibles and other cannabis.